Literature DB >> 2112201

Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma.

F L Meyskens, K Kopecky, M Samson, E Hersh, J Macdonald, H Jaffe, J Crowley, C Coltman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2112201     DOI： 10.1093/jnci/82.12.1071-a

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  16 in total

Review 1.  [Adjuvant therapy of melanoma. From non-specific immune stimulants into the future].

Authors:  A Hauschild; U R Kleeberg
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

Review 2.  The two faces of interferon-γ in cancer.

Authors:  M Raza Zaidi; Glenn Merlino
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

3.  Control of B-cell lymphoma by therapeutic vaccination and acquisition of immune resistance is independent of direct tumour IFN-gamma signalling.

Authors:  Rory Rearden; Amelia Sah; Brianna Doff; Takumi Kobayashi; Sara J McKee; Graham R Leggatt; Stephen R Mattarollo
Journal:  Immunol Cell Biol       Date:  2016-01-20       Impact factor: 5.126

Review 4.  Adjuvant therapy for melanoma: How should we respond to high-dose interferon?

Authors:  P G de Takats; M V Williams; R Hawkins
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

5.  Enhanced expression of interferon-gamma-induced antigen-processing machinery components in a spontaneously occurring cancer.

Authors:  Fulvia Cerruti; Marina Martano; Claudio Petterino; Enrico Bollo; Emanuela Morello; Renato Bruno; Paolo Buracco; Paolo Cascio
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

6.  The Interferon-Gamma Paradox in Cancer.

Authors:  M Raza Zaidi
Journal:  J Interferon Cytokine Res       Date:  2018-11-09       Impact factor: 2.607

Review 7.  Regulation of tumor growth by IFN-gamma in cancer immunotherapy.

Authors:  G L Beatty; Y Paterson
Journal:  Immunol Res       Date:  2001       Impact factor: 4.505

8.  In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target.

Authors:  Xiaoqing Wang; Collin Tokheim; Shengqing Stan Gu; Binbin Wang; Qin Tang; Yihao Li; Nicole Traugh; Zexian Zeng; Yi Zhang; Ziyi Li; Boning Zhang; Jingxin Fu; Tengfei Xiao; Wei Li; Clifford A Meyer; Jun Chu; Peng Jiang; Paloma Cejas; Klothilda Lim; Henry Long; Myles Brown; X Shirley Liu
Journal:  Cell       Date:  2021-09-27       Impact factor: 66.850

9.  Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression.

Authors:  Roberto Bellucci; Allison Martin; Davide Bommarito; Kathy Wang; Steen H Hansen; Gordon J Freeman; Jerome Ritz
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

10.  Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy.

Authors:  Mark J Dobrzanski
Journal:  Front Oncol       Date:  2013-03-26       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.